//
Also known as: C/O SOLOMON BLUM HEYMANN
Work at this foundation?
Claim this profile to manage it and see interest from grant seekers.
Emerald Foundation Inc. is a private corporation based in NEW YORK, NY. The foundation received its IRS ruling in 1998. The principal officer is Solomon Blum Heymann & Stich. It holds total assets of $25.3M. Annual income is reported at $11.3M. The foundation is governed by 5 officers and trustees. The foundation operates in the area of philanthropy & grantmaking. According to its most recent filing, the foundation only makes contributions to preselected charitable organizations. Tax records are available from 2016 to 2024. Funding is distributed across 4 states, including Massachusetts, New York, California. According to available records, Emerald Foundation Inc. has made 68 grants totaling $5.2M, with a median grant of $75K. Annual giving has grown from $1.1M in 2020 to $1.4M in 2023. Grantmaking activity was highest in 2021 with $1.4M distributed across 14 grants. Individual grants have ranged from $5K to $150K, with an average award of $77K. The foundation has supported 32 unique organizations. The foundation primarily supports organizations in Massachusetts, New York, California, which account for 66% of all grants. Grantmaking reaches organizations across 8 states. Contributions to this foundation are tax-deductible.
Smallest Grant
$75K
Median Grant
$113K
Average Grant
$113K
Largest Grant
$150K
Based on 10 grants from the most recent 990-PF filing.
No program descriptions are available for this foundation. Many private foundations report program activities in their annual 990-PF filings — check the Tax Filings section below for the most recent filing.
Emerald Foundation Inc. primarily funds organizations in the area of philanthropy & grantmaking. Based on available records, the foundation has funded 68 grants. Its grantmaking reaches organizations primarily in MA, NY, CA.
Emerald Foundation Inc. has distributed a total of $5.2M across 68 grants. The median grant size is $75K, with an average of $77K. Individual grants have ranged from $5K to $150K.
Emerald Foundation Inc. typically selects its grantees rather than accepting unsolicited proposals.
Emerald Foundation Inc. is headquartered in NEW YORK, NY. While based in NY, the foundation distributes grants to organizations across 8 states.
| Name | Title | Compensation | Benefits | Total |
|---|---|---|---|---|
| James P Mahaffey | Vice President | $119K | $0 | $119K |
| Erika Kellerhals | Director | $0 | $0 | N/A |
| William Blum | Treasurer | $0 | $0 | N/A |
| Luca Cantelli | Director | $0 | $0 | N/A |
| Andrew W Heymann | Pres/director | $0 | $0 | N/A |
Total Giving
N/A
Total Assets
$25.3M
Fair Market Value
N/A
Net Worth
$25.3M
Grants Paid
N/A
Contributions
N/A
Net Investment Income
N/A
Distribution Amount
N/A
Total Grants
68
Total Giving
$5.2M
Average Grant
$77K
Median Grant
$75K
Unique Recipients
32
Most Common Grant
$75K
of 2023 grantees were first-time recipients
| Recipient | Location | Amount | Year |
|---|---|---|---|
| University Of Md Baltimore FoundatiTO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | Baltimore, MD | $150K | 2023 |
| John Hopkins UniversityTO INVESTIGATE HOW THE COLON MICROBIOTA AND HOST GENETICS INTERSECT TO ALTER RESPONSIVENESS TO IMMUNOTHERAPY IN COLORECTAL CANCER. | Baltimore, MD | $100K | 2023 |
| Inserm Dr Grand OuestTO DETERMINE THE MECHANISM THROUGH WHICH BREAST CANCER CELL CLUSTERS DISSOCIATE INTO SINGLE CELLS AND PROLIFERATE AT DISTANT SITES AND TO DETERMINE THE IMPACT OF THE NEW ENVIRONMENT ON METASTASIS FORMATION. | Nantes | $100K | 2023 |
| Dana-Farber Cancer InstituteTO MAP THE TRANSCRIPTIONAL AND PROTEIN CHANGES INDUCED BY LACTATE AND IDENTIFY THE MECHANISMS THAT CAUSE NK SUPPRESSION, ON BOTH NK AND TUMOR CELLS, USING HIGH-THROUGHPUT AND UNBIASED APPROACHES. | Boston, MA | $100K | 2023 |
| University Of KyTO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | Lexington, KY | $100K | 2023 |
| Ma Institute Of TechnologyTO ENHANCE NANOPARTICLE ACCUMULATION IN DESIRED CELL TYPES TO DEVELOP MORE EFFECTIVE AND SAFER TARGETED NANOTHERAPIES. | Cambridge, MA | $75K | 2023 |
| Joan Sanford I Weill MedicalTO IDENTIFY REGULATORS OF LINEAGE REVERSION THAT IMPACT RESISTANCE TO WNT-TARGETED THERAPIES IN COLORECTAL CANCER. | New York, NY | $75K | 2023 |
| Whitehead Institute For BiomedTO UNCOVER THE SET OF CELL-SURFACE PROTEINS THAT MEDIATE ESSENTIAL INTERACTIONS BETWEEN PDAC CELLS AND THEIR MICROENVIRONMENT. | Cambridge, MA | $50K | 2023 |
| Salk Institute For Bio StudiesTO USE INNOVATIVE CELL BIOLOGY TECHNIQUES COUPLED WITH GENOMICS TO INVESTIGATE THE ROLE OF MITOCHONDRIAL-DERIVED VESICLES IN CANCER CELL METABOLISM. | La Jolla, CA | $50K | 2023 |
| President Fellows Of HarvardTO STUDY HOW SLC7A5 REGULATES METABOLIC REPROGRAMMING AND SIGNALING PATHWAYS THAT ENABLE CANCER CELLS TO SURVIVE CDK4/6I TREATMENT. | Boston, MA | $38K | 2023 |
| Ca Insitute Of TechnologyTO DEVELOP INTERPRETABLE MACHINE LEARNING METHODS THAT LINK SPATIAL PHENOTYPES IN IMAGING DATA OF SOLID TUMORS WITH PATIENT OUTCOMES. | Pasadena, CA | $38K | 2023 |
| Ca Institute Of TechnologyTO DEVELOP INTERPRETABLE MACHINE LEARNING METHODS THAT LINK SPATIAL PHENOTYPES IN IMAGING DATA OF SOLID TUMORS WITH PATIENT OUTCOMES. | Pasadena, CA | $38K | 2023 |
| Who We Play For IncTO SCREEN YOUNG STUDENTS FOR PREVIOUSLY UNDIAGNOSED HEART AILMENTS AND GENERATE DATA THAT CAN BE USED TO TRAIN AI PROGRAMS TO BETTER EVALUATE ELECTROCARDIOGRAMS. | Cocoa Beach, FL | $38K | 2023 |
| Institute For Cancer ResearchTO INVESTIGATE THE ROLE OF BRG1-DEPENDENT EPIGENETIC REGULATION ON PDAC FIBROBLAST PRO-TUMORIGENIC FUNCTIONS. | Philadelphia, PA | $38K | 2023 |
| Weill Med College Of Cornell UTO IDENTIFY REGULATORS OF LINEAGE REVERSION THAT IMPACT RESISTANCE TO WNT-TARGETED THERAPIES IN COLORECTAL CANCER. | New York, NY | $150K | 2022 |
| University Of GuelphTO IDENTIFY COMBINATIONS OF COMMERCIAL BACTERIAL ISOLATES THAT SUPPRESS KLEBSIELLA PNEUMONIAE IN THE COLON AND THE UNDERLYING COOPERATIVE MECHANISMS OF THIS ACTIVITY. | East Guelph | $100K | 2022 |
| Rockefeller UniversityTO INVESTIGATE THE ROLE OF TRNA-DERIVED FRAGMENTS AND THE GENES THEY REGULATE IN BREAST CANCER PROGRESSION AND METASTASIS. | New York, NY | $75K | 2022 |
| Univeristy Of Ca San FranciscoTO DEVELOP A SMALL MOLECULE THAT STABILIZES MUTANT P53 IN CANCER AND FURTHER ELABORATE THIS COMPOUND WITH THE ABILITY TO INCREASE DNA BINDING OF BOUND P53. | San Francisco, CA | $75K | 2022 |
| University Of Ca Santa BarbaraTO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | Santa Barbara, CA | $38K | 2022 |
| Massachusetts Institute Of TechnologyTo engance nanoparticle accumulation in desired cell types to develop more effective and safer targeted nanotherapies. | Cambridge, MA | $150K | 2021 |
| Brigham And Women'S Hospital IncTo uncover and validate druggable targets that can be combined with MEK/ERK inhibitors to treat RAS pathway-driven malignancies, especially melanoma. | Boston, MA | $150K | 2021 |
| Weill Cornell MedicineTo identify regulators of lineage reversion that impact resistance to WNT-targeted therapies in colorectal cancer. | New York, NY | $150K | 2021 |
| Whitehead Institute For Biomedical ResearchTo investigate the role of tRNA-derived fragments and the genes they regulate in breast cancer progression and metastasis. | Cambridge, MA | $100K | 2021 |